0000000000544690

AUTHOR

M Bartolini

showing 1 related works from this author

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct